placebo‐controlled, phase 3 trial. Lancet Oncol. 20: 806–815.(c) Yang, F., Zhao, N., Hu, Y. et al. (2020). The development process: from SAHA to hydroxamate HDAC inhibitors with branched CAP region and linear linker. Chem. Biodivers. 17: e1900427.(d) Zhang, Q., Wang, S., Chen, J., and Yu, Z. (2019). Histone deacetylases (HDACs) guided novel therapies for T‐cell lymphomas. Int. J. Med. Sci. 16: 424–442.109 109 Lu, X.P., Ning, Z.‐Q., Li, Z.‐B. et al. (2016). Successful Drug Discovery (ed. W.E.C.J. Fischer), 89–114. Weinheim: Wiley‐VCH.
110 110 Prusoff, W.H. (1959). Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. Biochim. Biophys. Acta 32: 295–296.
111 111 Clercq, E.D. and Holý, A. (2005). Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discovery 4: 928–940.
112 112 De Clercq, E., Descamps, J., De Somer, P., and Holy, A. (1978). (S)‐9‐(2,3‐Dihydroxypropyl)adenine: an aliphatic nucleoside analog with broad‐spectrum antiviral activity. Science 200: 563–565.
113 113 Declercq, E., Holy, A., Rosenberg, I. et al. (1986). A novel selective broad‐spectrum anti‐DNA virus agent. Nature 323: 464–467.
114 114 De Clercq, E., Sakuma, T., Baba, M. et al. (1987). Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 8: 261–272.
115 115 Pradere, U., Garnier‐Amblard, E.C., Coats, S.J. et al. (2014). Synthesis of nucleoside phosphate and phosphonate prodrugs. Chem. Rev. 114: 9154–9218.
116 116 Wittayanarakul, K., Aruksakunwong, O., Saen‐Oon, S. et al. (2005). Insights into saquinavir resistance in the G48V HIV‐1 protease: quantum calculations and molecular dynamic simulations. Biophys. J. 88: 867–879.
117 117 Ghosh, A.K., Sridhar, P.R., Leshchenko, S. et al. (2006). Structure‐based design of novel HIV‐1 protease inhibitors to combat drug resistance. J. Med. Chem. 49: 5252–5261.
118 118 (a) Ghosh, A.K., Anderson, D.D., Weber, I.T., and Mitsuya, H. (2012). Enhancing protein backbone binding – a fruitful concept for combating drug‐resistant HIV. Angew. Chem. Int. Ed. 51: 1778–1802.(b) Ghosh, A.K., Chapsal, B.D., Weber, I.T., and Mitsuya, H. (2008). Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. Acc. Chem. Res. 41: 78–86.
119 119 Surleraux, D.L., Tahri, A., Verschueren, W.G. et al. (2005). Discovery and selection of TMC114, a next generation HIV‐1 protease inhibitor. J. Med. Chem. 48: 1813–1822.
120 120 King, N.M., Prabu‐Jeyabalan, M., Nalivaika, E.A. et al. (2004). Structural and thermodynamic basis for the binding of TMC114, a next‐generation human immunodeficiency virus type 1 protease inhibitor. J. Virol. 78: 12012–12021.
121 121 Umezawa, H., Imoto, M., Sawa, T. et al. (1986). Studies on a new epidermal growth factor‐receptor kinase inhibitor, erbstatin, produced by MH435‐hF3. J. Antibiot. (Tokyo) 39: 170–173.
122 122 Mohammadi, M., McMahon, G., Sun, L. et al. (1997). Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276: 955–960.
123 123 Union, O.E. (2018). Health at a Glance: Europe 2018: State of Health in the EU Cycle, vol. 2020. Paris/Brussels: OECD Publishing/European Union.
124 124 NIH (2018). NIH Central Resource for Grants and Funding Information - Peer review, Vol. 2020, https://grants.nih.gov/grants/peer-review.htm (accessed 18 May 2020).
Biography
Oliver Plettenburg studied chemistry at the University of Wuppertal and obtained his PhD under the supervision of Prof. Hans‐Josef Altenbach in 2000. He then moved to The Scripps Research Institute, La Jolla, to work under the guidance of Prof. Chi‐Huey Wong, where he focused on the synthesis of glycolipids. After this he joined the pharmaceutical industry at Aventis Pharma, working first in classical medicinal chemistry and developing projects from hit and lead optimization phase all the way to early clinical trials. Later he was more and more involved in establishing alternative concepts in pharmaceutical research, and lastly he held positions as “Head of Chemical Biology” and “Head of Biosensors and Chemical Probes” at Sanofi‐Aventis, Frankfurt, Germany. From 2016, Dr. Plettenburg serves as founding director of the Institute of Medicinal Chemistry of the Helmholtz Center Munich, and he is also a full professor for Medicinal Chemistry at Leibniz Universität Hannover. His research focuses on hit and lead optimization to open up new treatment options for severe diseases like diabetes, lung, inflammatory, or infectious diseases. Furthermore, he develops innovative targeted and smart drug delivery methods and works on the synthesis of novel imaging agents for in vivo monitoring of pathogenesis.
Конец ознакомительного фрагмента.
Текст предоставлен ООО «ЛитРес».
Прочитайте эту книгу целиком, купив полную легальную версию на ЛитРес.
Безопасно оплатить книгу можно банковской картой Visa, MasterCard, Maestro, со счета мобильного телефона, с платежного терминала, в салоне МТС или Связной, через PayPal, WebMoney, Яндекс.Деньги, QIWI Кошелек, бонусными картами или другим удобным Вам способом.
